


Dilmapimod

Cat. No.:	HY-10404		
CAS No.:	444606-18-2		
Molecular Formula:	C ₂₃ H ₁₉ F ₃ N ₄ O ₃		
Molecular Weight:	456.42		
Target:	p38 MAPK; Autophagy		
Pathway:	MAPK/ERK Pathway; Autophagy		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (273.87 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.1910 mL	10.9548 mL	21.9096 mL
		5 mM	0.4382 mL	2.1910 mL	4.3819 mL
10 mM		0.2191 mL	1.0955 mL	2.1910 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.56 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.56 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.56 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
In Vitro	Dilmapimod (SB-681323) potently inhibits p38 MAPK signaling, measured by inhibition of sorbitol-induced pHSP27 expression ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell. 2020 Aug 6;182(3):685-712.e19.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Singh D, et al. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol. 2010 Jan;50(1):94-100.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA